Literature DB >> 27087693

Maturation of Lesions Induced by Myocardial Cavitation-Enabled Therapy.

Xiaofang Lu1, Douglas L Miller2, Chunyan Dou2, Yiying I Zhu2, Mario L Fabiilli2, Gabe E Owens2, Oliver D Kripfgans2.   

Abstract

Myocardial contrast echocardiography at enhanced therapeutic parameters may be a novel means of tissue reduction therapy, as for hypertrophic cardiomyopathy. Dahl/SS rats were anesthetized and treated with high-amplitude pulsed ultrasound guided by 10-MHz ultrasound images. Contrast microbubbles were infused via the tail vein during intermittent pulse-burst exposure at 4 MPa. A sham group, a low-impact group (group A, 5 cycle pulses with Gaussian modulation and 1:4 trigger for 5 min) and a high-impact group (group B, 10 cycle pulses with 4-ms square modulation and 1:8 trigger for 10 min) were tested. The higher exposure used in group B yielded more substantial injury than the lower exposure in group A. Treated rats in both groups A and B had significant increases in wall thickness measured by echocardiography the next day, which returned to normal by the end of 6 wk. Six weeks after ultrasound exposure, heart tissue samples exhibited tissue fibrosis in Masson's trichrome stained histology. Maturation of lesions involved fibrosis replacement, preserving structural tissue integrity. This study indicates that myocardial injury noted previously progresses into permanent loss of myocardial tissue that may be sufficient for possible hypertrophic cardiomyopathy therapy. More research is needed to define the treatment parameters required for symptomatic relief for hypertrophic cardiomyopathy.
Copyright © 2016 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypertrophic cardiomyopathy treatment; Tissue reduction therapy; Ultrasonic cavitation microlesions; Ultrasound therapy

Mesh:

Substances:

Year:  2016        PMID: 27087693      PMCID: PMC4899230          DOI: 10.1016/j.ultrasmedbio.2016.02.006

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  22 in total

1.  Ventricular remodeling after acute myocardial infarction: effect of low-intensity laser irradiation.

Authors:  P Whittaker; M J Patterson
Journal:  Lasers Surg Med       Date:  2000       Impact factor: 4.025

2.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

3.  Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution.

Authors:  Folkert J ten Cate; Osama I I Soliman; Michelle Michels; Dominic A M J Theuns; Peter L de Jong; Marcel L Geleijnse; Patrick W Serruys
Journal:  Circ Heart Fail       Date:  2010-03-23       Impact factor: 8.790

Review 4.  Cardiovascular therapeutic uses of targeted ultrasound contrast agents.

Authors:  Susan T Laing; David D McPherson
Journal:  Cardiovasc Res       Date:  2009-07-06       Impact factor: 10.787

5.  Influence of contrast agent dose and ultrasound exposure on cardiomyocyte injury induced by myocardial contrast echocardiography in rats.

Authors:  Douglas L Miller; Peng Li; Chunyan Dou; David Gordon; Chris A Edwards; William F Armstrong
Journal:  Radiology       Date:  2005-10       Impact factor: 11.105

6.  Use of Theranostic Strategies in Myocardial Cavitation-Enabled Therapy.

Authors:  Douglas L Miller; Chunyan Dou; Xiaofang Lu; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2015-04-15       Impact factor: 2.998

Review 7.  New perspectives on the prevalence of hypertrophic cardiomyopathy.

Authors:  Christopher Semsarian; Jodie Ingles; Martin S Maron; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

8.  An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.

Authors:  Maciej Dąbrowski; Lidia Chojnowska; Lukasz Małek; Mateusz Spiewak; Beata Kuśmierczyk; Jacek Koziarek; Anna Klisiewicz; Jolanta Miśko; Adam Witkowski
Journal:  Kardiol Pol       Date:  2012       Impact factor: 3.108

9.  Substitution of Brown Norway chromosome 16 preserves cardiac function with aging in a salt-sensitive Dahl consomic rat.

Authors:  A J Kriegel; A S Greene
Journal:  Physiol Genomics       Date:  2008-10-21       Impact factor: 3.107

10.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Hicham El Masry; Jeffrey A Breall
Journal:  Curr Cardiol Rev       Date:  2008-08
View more
  2 in total

1.  Ultrasonic Cavitation-Enabled Treatment for Therapy of Hypertrophic Cardiomyopathy: Proof of Principle.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Rachael Fuller; Kristina Fields; Mario L Fabiilli; Gabe E Owens; David Gordon; Oliver D Kripfgans
Journal:  Ultrasound Med Biol       Date:  2018-04-19       Impact factor: 2.998

2.  Multiple ultrasound cavitation-enabled treatments for myocardial reduction.

Authors:  Douglas L Miller; Xiaofang Lu; Chunyan Dou; Yiying I Zhu; Mario L Fabiilli; Gabe E Owens; Oliver D Kripfgans
Journal:  J Ther Ultrasound       Date:  2017-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.